dantrolene has been researched along with Muscle Spasticity in 96 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
Muscle Spasticity: A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a free interval) followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)." | 9.27 | Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
| "A double-blind study was carried out on 20 children with spasticity secondary to cerebral palsy, in order to compare the effects of dantrolene sodium suspension and a placebo." | 9.05 | Dantrolene sodium suspension in treatment of spastic cerebral palsy. ( Joynt, RL; Leonard, JA, 1980) |
| "Seventy-seven patients with muscle spasticity secondary to central nervous system pathology were treated with dantrolene sodium for periods of up to two years." | 9.04 | Dantrolene sodium: long-term effects in patients with muscle spasticity. ( Joynt, RL, 1976) |
| "In this two-phase study, 21 pediatric patients with epilepsy and spasticity were initially treated with dantrolene sodium suspension and, after a washout period, began a double-blind portion where one half received dantrolene sodium suspension and the other half received a placebo suspension." | 9.04 | Effect of dantrolene sodium on the incidence of seizures in children with spasticity. ( Nogen, AG, 1979) |
| "We report the case of a patient who developed dantrolene-induced pleurisy." | 7.70 | [Dantrolene-induced pleurisy: a case report]. ( Dohen, F; Lelieur, E; Montagne, V, 2000) |
| "A 29-year-old man with C6 tetraplegia (ASIA A) using an implanted baclofen pump and intrathecal catheter infusion system for spasticity control developed severe spasticity, hyperthermia, hypotension, rhabdomyolysis, and disseminated intravascular coagulation after catheter disconnection." | 7.70 | Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure. ( Christopherson, MW; Reeves, RK; Stolp-Smith, KA, 1998) |
| "A patient developed pulmonary infiltration, pleural effusions and pericarditis three months after starting dantrolene sodium." | 7.67 | Pneumonitis, pleural effusion and pericarditis following treatment with dantrolene. ( Haas, LF; Miller, DH, 1984) |
| "We describe two cases of an unusual acneiform eruption which occurred in middle aged women being treated with dantrolene for spasticity." | 7.66 | Acne induced by dantrolene. ( Kataria, M; Pembroke, AC; Saxena, SR; Zilkha, KD, 1981) |
| "Dantrolene has also been used successfully in the treatment of a few cases of heat stroke and the neuroleptic malignant syndrome--both of which have many similarities to malignant hyperthermia." | 6.37 | Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. ( Chaffman, MO; Sorkin, EM; Ward, A, 1986) |
| "A quadriplegic patient with severe spasticity, treated with dantrolene (400 mg daily) for 5 years, had dyspnea, orthopnea, hypoxia, and right-sided opacity of the chest on radiograph." | 5.31 | Eosinophilic pleural effusion due to dantrolene: resolution with steroid therapy. ( Felz, MW; Haviland-Foley, DJ, 2001) |
| "Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)." | 5.27 | Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
| "A double-blind study was carried out on 20 children with spasticity secondary to cerebral palsy, in order to compare the effects of dantrolene sodium suspension and a placebo." | 5.05 | Dantrolene sodium suspension in treatment of spastic cerebral palsy. ( Joynt, RL; Leonard, JA, 1980) |
| "In this two-phase study, 21 pediatric patients with epilepsy and spasticity were initially treated with dantrolene sodium suspension and, after a washout period, began a double-blind portion where one half received dantrolene sodium suspension and the other half received a placebo suspension." | 5.04 | Effect of dantrolene sodium on the incidence of seizures in children with spasticity. ( Nogen, AG, 1979) |
| "Seventy-seven patients with muscle spasticity secondary to central nervous system pathology were treated with dantrolene sodium for periods of up to two years." | 5.04 | Dantrolene sodium: long-term effects in patients with muscle spasticity. ( Joynt, RL, 1976) |
| "The effects of dantrolene sodium and diazepam were compared in a double crossover study of 42 patients with spasticity due to stable multiple sclerosis." | 5.04 | Comparison of dantrolene sodium and diazepam in the treatment of spasticity. ( Lee, RH; Schmidt, RT; Spehlmann, R, 1976) |
| "Dantrolene can be combined with baclofen to better treat spasticity, but may cause muscular weakness and dysphagia." | 3.80 | Pharyngeal spasticity due to dantrolene. ( Amorelli, V; Avantaggiato, P; Clementi, E; Galbiati, S; Lanfranchi, M; Locatelli, F; Pozzi, M; Radice, S; Rizzi, G; Strazzer, S; Tufarulo, L, 2014) |
| "We report the case of a patient who developed dantrolene-induced pleurisy." | 3.70 | [Dantrolene-induced pleurisy: a case report]. ( Dohen, F; Lelieur, E; Montagne, V, 2000) |
| "A 29-year-old man with C6 tetraplegia (ASIA A) using an implanted baclofen pump and intrathecal catheter infusion system for spasticity control developed severe spasticity, hyperthermia, hypotension, rhabdomyolysis, and disseminated intravascular coagulation after catheter disconnection." | 3.70 | Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure. ( Christopherson, MW; Reeves, RK; Stolp-Smith, KA, 1998) |
| "A patient developed pulmonary infiltration, pleural effusions and pericarditis three months after starting dantrolene sodium." | 3.67 | Pneumonitis, pleural effusion and pericarditis following treatment with dantrolene. ( Haas, LF; Miller, DH, 1984) |
| "The author's clinical experience with the use of dantrolene in children with cerebral palsy is discussed." | 3.67 | Long-term treatment of spasticity in children with cerebral palsy. ( Molnar, GE, 1987) |
| "We describe two cases of an unusual acneiform eruption which occurred in middle aged women being treated with dantrolene for spasticity." | 3.66 | Acne induced by dantrolene. ( Kataria, M; Pembroke, AC; Saxena, SR; Zilkha, KD, 1981) |
| "A patient is reported who was on prolonged treatment with dantrolene for spastic paraplegia; he developed a malignant lymphoma which led to his death." | 3.66 | Dantrolene and lymphocytic lymphoma. ( Tucker, JS; Wan, HH, 1980) |
| "The mode of action of dantrolene sodium was studied in 11 multiple sclerosis patients with spastic paresis of the legs by measurements of changes in electromyographic and mechanomyographic proprioceptive reflex responses and in voluntary power." | 3.66 | Mode of action of dantrolene sodium in spasticity. ( Mai, J; Pedersen, E, 1979) |
| "Forty patients, whose ages varied from 4 to 65 years, presenting skeletal muscle spascitiy as sequel of cerebral palsy, spinovertebral trauma and cerebral vascular diseases were treated with Dantrium (dantrolene sodium), a drug muscle relaxing." | 3.65 | [Sodium dantrolene (dantrium) in the treatment of neurogenic muscular spasm]. ( Alvarenga, H; Araújo Leitão, RE; Couto, B; Figuereido, HB; Gomes Marleide, M; Melo Reis, CH, 1976) |
| " Dantrium produced no alteration in clinical tone, functional outcome, or biochemical tests at the dosage (200 mg per day) used in this study." | 2.67 | Objective assessment of spasticity, strength, and function with early exhibition of dantrolene sodium after cerebrovascular accident: a randomized double-blind study. ( Cole, AM; Katrak, PH; McCauley, JC; Poulos, CJ, 1992) |
| "The results indicate that the spasticity of cerebral palsy can be relieved significantly, and that the combination of peripherally and centrally acting agents is more beneficial than either medication alone." | 2.64 | Medical treatment for spasticity in children with cerebral palsy. ( Nogen, AG, 1976) |
| "The available studies on spasticity treatment offer some insight to guide clinical practice but are of variable methodological quality." | 2.53 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016) |
| "The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol." | 2.48 | [Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012) |
| "For more generalized spasticity, a number of useful oral agents and intrathecal baclofen are available, each with their positive and negative attributes." | 2.46 | Pharmacologic treatment of spasticity in children. ( Delgado, MR; Tilton, A; Vargus-Adams, J, 2010) |
| "Gabapentin is a novelty, and the working mechanism of cannabis has been elucidated." | 2.46 | Spasticity: revisiting the role and the individual value of several pharmacological treatments. ( Kuks, JB; Lapeyre, E; Meijler, WJ, 2010) |
| "While in some children, spasticity may adversely impact the motor abilities, in others, it may help maintain posture and ability to ambulate." | 2.43 | Pharmacologic interventions for reducing spasticity in cerebral palsy. ( Patel, DR; Soyode, O, 2005) |
| "The spectrum of antispasticity therapies is fairly broad." | 2.43 | The pharmacological management of spasticity. ( Jacobs, BW; Saulino, M, 2006) |
| "Dantrolene is a skeletal muscle relaxant that depresses the excitation-contraction coupling,however, the specificity of action remains unknown." | 2.42 | [Dantrolene. Pharmacological and therapeutic aspects]. ( Agarwal, K; Fiege, M; Gerbershagen, MU; Krause, T; Wappler, F, 2003) |
| "Therapy for spasticity is symptomatic with the aim of increasing functional capacity and relieving discomfort." | 2.41 | Drugs used to treat spasticity. ( Goodkin, DE; Kita, M, 2000) |
| "Among the more common symptoms is spasticity." | 2.41 | Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001) |
| "The functional impairment due to spasticity must be carefully assessed before any treatment is considered." | 2.37 | Management of spasticity. ( Katz, RT, 1988) |
| "Tizanidine has been recently introduced, and early experience with this agent appears to be favourable." | 2.37 | Pharmacotherapy of spasticity: some theoretical and practical considerations. ( Rice, GP, 1987) |
| "Dantrolene is a direct acting muscle relaxant which should be avoided in patients with pre-existing liver damage." | 2.37 | Spasticity and drug therapy. ( Wuis, EW, 1987) |
| "Dantrolene has also been used successfully in the treatment of a few cases of heat stroke and the neuroleptic malignant syndrome--both of which have many similarities to malignant hyperthermia." | 2.37 | Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. ( Chaffman, MO; Sorkin, EM; Ward, A, 1986) |
| "Fewer than 5% of subjects changed oral spasticity medications." | 1.39 | Adherence associated with oral medications in the treatment of spasticity. ( Gillard, P; Graham, GD; Halpern, R; Varon, SF; Zorowitz, RD, 2013) |
| "A quadriplegic patient with severe spasticity, treated with dantrolene (400 mg daily) for 5 years, had dyspnea, orthopnea, hypoxia, and right-sided opacity of the chest on radiograph." | 1.31 | Eosinophilic pleural effusion due to dantrolene: resolution with steroid therapy. ( Felz, MW; Haviland-Foley, DJ, 2001) |
| "Motor point blocks may partially dampen spasticity in selected muscles of some patients." | 1.26 | Management of spasticity in spinal cord injury. ( Merritt, JL, 1981) |
| "In 25 patients with spasticity, pharmacokinetics and effects of dantrolene sodium were investigated after prolonged administration." | 1.26 | The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration. ( Agoston, S; Bakker, H; Kok, JJ; Meyler, WJ; Wesseling, H, 1981) |
| "Dantrolene sodium was effective in controlling spasticity and improving function in 11 of 13 patients taking part in a 14-week double-blind crossover study." | 1.25 | Efficacy of dantrolene sodium in the treatment of spasticity. ( Chipman, M; Kaul, S; Lambie, M, 1974) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 63 (65.63) | 18.7374 |
| 1990's | 8 (8.33) | 18.2507 |
| 2000's | 15 (15.63) | 29.6817 |
| 2010's | 10 (10.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sturgill, EL | 1 |
| Wittwer, RL | 1 |
| Creamer, M | 1 |
| Cloud, G | 1 |
| Kossmehl, P | 1 |
| Yochelson, M | 1 |
| Francisco, GE | 1 |
| Ward, AB | 1 |
| Wissel, J | 1 |
| Zampolini, M | 1 |
| Abouihia, A | 1 |
| Calabrese, A | 1 |
| Saltuari, L | 1 |
| Halpern, R | 1 |
| Gillard, P | 1 |
| Graham, GD | 1 |
| Varon, SF | 1 |
| Zorowitz, RD | 1 |
| Lipták, J | 1 |
| Locatelli, F | 1 |
| Pozzi, M | 1 |
| Avantaggiato, P | 1 |
| Lanfranchi, M | 1 |
| Tufarulo, L | 1 |
| Amorelli, V | 1 |
| Rizzi, G | 1 |
| Radice, S | 1 |
| Galbiati, S | 1 |
| Clementi, E | 1 |
| Strazzer, S | 1 |
| Otero-Romero, S | 1 |
| Sastre-Garriga, J | 1 |
| Comi, G | 1 |
| Hartung, HP | 1 |
| Soelberg Sørensen, P | 1 |
| Thompson, AJ | 1 |
| Vermersch, P | 1 |
| Gold, R | 1 |
| Montalban, X | 1 |
| Kasatkin, DS | 1 |
| Mowbray, M | 1 |
| Sinclair, SA | 1 |
| Allan, SJ | 1 |
| Lapeyre, E | 1 |
| Kuks, JB | 1 |
| Meijler, WJ | 1 |
| Tilton, A | 1 |
| Vargus-Adams, J | 1 |
| Delgado, MR | 1 |
| Chung, CY | 1 |
| Chen, CL | 1 |
| Wong, AM | 1 |
| Heinzlef, O | 1 |
| Monteil-Roch, I | 1 |
| Gerbershagen, MU | 1 |
| Fiege, M | 1 |
| Krause, T | 1 |
| Agarwal, K | 1 |
| Wappler, F | 1 |
| Zafonte, R | 1 |
| Lombard, L | 1 |
| Elovic, E | 2 |
| Yelnik, AP | 1 |
| Patel, DR | 1 |
| Soyode, O | 1 |
| Okada, M | 1 |
| Nakagawa, E | 1 |
| Masuyama, T | 1 |
| Fujikawa, Y | 1 |
| Komaki, H | 1 |
| Sugai, K | 1 |
| Sasaki, M | 1 |
| Taricco, M | 1 |
| Pagliacci, MC | 1 |
| Telaro, E | 1 |
| Adone, R | 1 |
| Saulino, M | 1 |
| Jacobs, BW | 1 |
| Chipman, M | 1 |
| Kaul, S | 1 |
| Lambie, M | 1 |
| Britt, BA | 1 |
| Pedersen, E | 3 |
| Young, RR | 2 |
| Delwaide, PJ | 2 |
| Pembroke, AC | 1 |
| Saxena, SR | 1 |
| Kataria, M | 1 |
| Zilkha, KD | 1 |
| Ketel, WB | 1 |
| Kolb, ME | 1 |
| McLellan, DL | 1 |
| Miller, DH | 1 |
| Haas, LF | 1 |
| Mårtensson, A | 2 |
| Delaney, JF | 1 |
| Wan, HH | 1 |
| Tucker, JS | 1 |
| Knutsson, E | 2 |
| Dimitrijevic, MR | 1 |
| Sherwood, AM | 1 |
| Joynt, RL | 2 |
| Leonard, JA | 1 |
| Winnem, M | 1 |
| DeLisa, JA | 1 |
| Little, J | 1 |
| Melnick, ME | 1 |
| Shellenberger, MK | 1 |
| Meyler, WJ | 2 |
| Bakker, H | 1 |
| Kok, JJ | 1 |
| Agoston, S | 1 |
| Wesseling, H | 2 |
| Tibbs, PA | 1 |
| Young, AB | 1 |
| Walsh, JW | 1 |
| Bean, JR | 1 |
| Merritt, JL | 1 |
| Leslie, GC | 1 |
| Part, NJ | 1 |
| Burton, L | 1 |
| McDowell, FH | 1 |
| Varghese, G | 1 |
| Redford, JB | 1 |
| Chantraine, A | 1 |
| van Ouwenaller, C | 1 |
| Khorasani, A | 1 |
| Peruzzi, WT | 1 |
| Barnes, MP | 1 |
| Bodensteiner, JB | 1 |
| Morel, N | 1 |
| Reeves, RK | 1 |
| Stolp-Smith, KA | 1 |
| Christopherson, MW | 1 |
| Kita, M | 1 |
| Goodkin, DE | 1 |
| Dohen, F | 1 |
| Montagne, V | 1 |
| Lelieur, E | 1 |
| Felz, MW | 1 |
| Haviland-Foley, DJ | 1 |
| Schapiro, RT | 1 |
| Davidoff, RA | 2 |
| Mai, J | 1 |
| Pinder, RM | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Korczyn, AD | 1 |
| Galinsky, D | 1 |
| Berginer, VM | 1 |
| Goren, C | 1 |
| Weiser, R | 1 |
| Terenty, T | 1 |
| Hudgson, P | 1 |
| Weightman, D | 1 |
| Nogen, AG | 2 |
| Khondkarian, OA | 1 |
| Zavalishin, IA | 1 |
| Novikova, VP | 1 |
| Mols-Thürkow, HW | 1 |
| Petusevsky, ML | 1 |
| Faling, LJ | 1 |
| Rocklin, RE | 1 |
| Snider, GL | 1 |
| Merliss, AD | 1 |
| Moses, JM | 1 |
| Dorman, SA | 1 |
| Harving, H | 1 |
| Klemar, B | 1 |
| van Laere, M | 1 |
| Leus, P | 1 |
| Mastelinck, C | 1 |
| Schmidt, RT | 1 |
| Lee, RH | 1 |
| Spehlmann, R | 1 |
| Basmajian, JV | 3 |
| Walsh, EG | 1 |
| Gautier-Smith, PC | 1 |
| Couto, B | 1 |
| Figuereido, HB | 1 |
| Araújo Leitão, RE | 1 |
| Alvarenga, H | 1 |
| Gomes Marleide, M | 1 |
| Melo Reis, CH | 1 |
| Dykes, MH | 1 |
| Katrak, PH | 1 |
| Cole, AM | 1 |
| Poulos, CJ | 1 |
| McCauley, JC | 1 |
| Dietz, V | 1 |
| Satoyoshi, E | 1 |
| Molnar, GE | 1 |
| Azouvi, P | 1 |
| Roby-Brami, A | 1 |
| Tougeron, A | 1 |
| Bussel, B | 1 |
| Katz, RT | 1 |
| Rice, GP | 1 |
| Wuis, EW | 1 |
| Ward, A | 1 |
| Chaffman, MO | 1 |
| Sorkin, EM | 1 |
| Ducamp, E | 1 |
| Albin, H | 1 |
| Barat, M | 1 |
| Ladd, H | 1 |
| Oist, C | 1 |
| Jonsson, B | 1 |
| Herman, R | 1 |
| Freedman, W | 1 |
| Mayer, N | 1 |
| Shaivitz, SA | 1 |
| Ladd, HW | 1 |
| Gingras, G | 1 |
| Boucher, J | 1 |
| Kazdan, N | 1 |
| Keenan, R | 1 |
| Glass, A | 1 |
| Hannah, A | 1 |
| Gelenberg, AJ | 1 |
| Poskanzer, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment[NCT01032239] | Phase 4 | 61 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595] | 36 participants (Anticipated) | Interventional | 2023-05-18 | Recruiting | |||
| The Use of Penile Vibratory Stimulation to Decrease Spasticity Following Spinal Cord Injury[NCT00223873] | 30 participants | Interventional | 2002-11-30 | Completed | |||
| The Effects of EXOPULSE Mollii Suit on Motor Functions in Patients With Multiple Sclerosis (EXOSEP 2)[NCT05857280] | 36 participants (Anticipated) | Interventional | 2023-03-21 | Recruiting | |||
| To Estimate the Efficacy of Botulinum Toxin A Injection Combing With Exoskeleton Robotic Assisted Gait Training in Stroke Patients With Spastic Stiff Knee Gait: Motor Function Performance and Neurophysiological Evaluation[NCT06070987] | 36 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in average 10MTWT from baseline to month 6 beetween ITB and BMT arm. Change=10MTWT at month 6 - 10MTWT at baseline (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | seconds (Mean) |
|---|---|
| ITB Therapy | 4.86 |
| Best Medical Treatment (BMT) | -2.48 |
"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the lower extremities were assessed: hip flexors, hip adductors, knee extensors, knee flexors, plantar flexors and ankle-dorsal flexors. Average AS was calculated as the average of AS scores of the 6 muscles of the affected lower extremity. Change in average AS in affected lower extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) |
|---|---|
| ITB Therapy | -0.99 |
| Best Medical Treatment (BMT) | -0.43 |
"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the upper extremities were assessed: wrist flexors, elbow flexors, elbow extensors, shoulder abductors and shoulder adductors. Average AS was calculated as the average of AS scores of the 5 muscles of the affected lower extremities. Change in average AS in affected upper extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) |
|---|---|
| ITB Therapy | -0.66 |
| Best Medical Treatment (BMT) | -0.17 |
FIM contains 18 items composed of 13 motor tasks and 5 cognitive tasks. Tasks are rated on a 7-point ordinal scale that ranges from total assistance (or complete dependence) to complete independence. Ratings should reflect actual observed performance, not capability. Total score ranges from 18 (lowest) to 126 (highest) level of independence. Change in FIM total score from baseline to month 6 between ITB and BMT arm was assessed. Change=FIM score at month 6 - FIM score at baseline. (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) |
|---|---|
| ITB Therapy | 2.68 |
| Best Medical Treatment (BMT) | -2.58 |
"SS-QoL questionnaire is a self-assessed quality of life questionnaire specifically designed for post-stroke patients. It evaluates 49 items across 12-domains: personality, energy, language, mobility, vision, upper extremity function, thinking, mood, work/productivity, self-care, and family and social roles. Each item is rated on a 5-point Likert Scale, measuring either positive or negative response to a statement. Summary score is composed of an unweighted average of the 12 domain scores, with higher scores indicating better QoL. Total score ranges from 1 to 5. Change in SS-QoL summary score from baseline to month 6 between ITB and BMT arm was assessed.~Change=SS-QoL score at month 6 - SS-QoL score at baseline." (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) |
|---|---|
| ITB Therapy | 0.26 |
| Best Medical Treatment (BMT) | 0.05 |
"The EQ-5D-3L is a generic measure of health status consisting in the EQ-5D-3L descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system is characterized on five dimensions: mobility, self-care, ability to undertake usual activities, pain and anxiety/depression. Patients were asked to indicate their level of health on each dimension using one of three levels: no health problems, moderate health problems, and severe health problems. Responses from the questionnaire were converted to a single health index utility score; this ranges from -0.595 to 1. EQ VAS records the patient's self-rated health on a vertical visual analogue scale from 0 to 100 where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0). Change in EQ-5D-3L utility score and VAS score from baseline to month 6 between ITB and BMT arm were assessed. Change=EQ-5D-3L utility or VAS score at month 6 - EQ-5D-3L utility or VAS score." (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Utility Score | VAS | |
| Best Medical Treatment (BMT) | 0.01 | 4.40 |
| ITB Therapy | 0.09 | 9.68 |
"NPRS is designed to assess the level of pain a patient is feeling at a point in time. The following questions has been presented to patients: What is your actual spasticity-related or spasm-related pain? What was your least spasticity-related or spasm-related pain during the last week? What was your worst spasticity-related or spasm-related pain during the last week? The patient indicated how much pain he is feeling on a scale from 0 to 10. A score of 0 (zero) is no pain while a score of 10 (ten) is worst possible pain. Change in NPRS related to actual, least or worst pain from baseline to month 6 between ITB and BMT arm was assessed. Change=NPRS at month 6 - NPRS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Actual pain | Least Pain | Worst Pain | |
| Best Medical Treatment (BMT) | 0.00 | 0.24 | -0.04 |
| ITB Therapy | -1.17 | -1.61 | -1.35 |
The SF-12 is generic assessment of health-related quality of life, which evaluates 8 health dimensions (physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, mental health, and general health). Subscale scores for each dimension were aggregated into summary scores for physical (PCS) and mental health (MCS) components (ranging from 0 to 100, with higher scores indicating better health). Changes in the PCS and MCS from baseline to Month 6 were both compared between the BMT and ITB arms. Change=SF-12 score at month 6 - SF-12 score at baseline. (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) | |
|---|---|---|
| PCS | MCS | |
| Best Medical Treatment (BMT) | -1.13 | -0.82 |
| ITB Therapy | 3.13 | 1.05 |
Number of patients with healthcare professional contacts outside of study visits in the ITB and BMT between baseline and months 6 (NCT01032239)
Timeframe: baseline, ITB test (only ITB arm), second assessment (only BMT arm), week 6 (only ITB arm), month 3, month 6
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline : general practitioner | Baseline : neurologist | Baseline : nurse (hospital setting) | Baseline : nurse (home care) | Baseline : orthopedic surgeon | Baseline : other | ITB test:general practitioner | ITB test: neurologist | ITB test :other | Second Assessment: general practitioner | Second Assessment: neurologist | Second Assessment: nurse (home care) | Second Assessment: other | week 6: general practitioner | week 6: nurse (hospital setting) | week 6: other | month 3: general practitioner | month 3: neurologist | month 3: other | month 6: general practitioner | month 6: neurologist | month 6: other | |
| Best Medical Treatment (BMT) | 8 | 8 | 0 | 1 | 0 | 13 | NA | NA | NA | 5 | 1 | 1 | 4 | NA | NA | NA | 8 | 3 | 9 | 7 | 2 | 11 |
| ITB Therapy | 14 | 4 | 1 | 0 | 3 | 10 | 1 | 1 | 3 | NA | NA | NA | NA | 4 | 2 | 2 | 7 | 1 | 6 | 8 | 3 | 8 |
Patient was asked to transfer from the wheelchair to bed without human assistance. High level functional patient (HLP) could transfer. Low level functional patient (LLP) was not able to transfer. Comparison of the number and percentage of HLP and LLP between ITB and BMT arms was evaluated. (NCT01032239)
Timeframe: baseline, month 3, month 6
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline72364475 | Baseline72364476 | Month 372364475 | Month 372364476 | Month 672364475 | Month 672364476 | |||||||
| HLP | LLP | |||||||||||
| ITB Therapy | 22 | |||||||||||
| Best Medical Treatment (BMT) | 24 | |||||||||||
| ITB Therapy | 9 | |||||||||||
| Best Medical Treatment (BMT) | 21 | |||||||||||
| ITB Therapy | 6 | |||||||||||
| ITB Therapy | 19 | |||||||||||
| Best Medical Treatment (BMT) | 19 | |||||||||||
| ITB Therapy | 5 | |||||||||||
| Best Medical Treatment (BMT) | 5 | |||||||||||
"Patients were presented with two statements (I am satisfied with the reduction in spasticity provided by my treatment, and I would recommend this therapy to a friend). They agreed, disagreed or were neutral with the statements." (NCT01032239)
Timeframe: month 6
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient Satisfaction with Spasticity Reduction72364475 | Patient Satisfaction with Spasticity Reduction72364476 | Patient Therapy Reccomandation72364475 | Patient Therapy Reccomandation72364476 | |||||||||
| disagree | neutral | agree | ||||||||||
| ITB Therapy | 2 | |||||||||||
| Best Medical Treatment (BMT) | 7 | |||||||||||
| ITB Therapy | 4 | |||||||||||
| ITB Therapy | 16 | |||||||||||
| Best Medical Treatment (BMT) | 11 | |||||||||||
| Best Medical Treatment (BMT) | 5 | |||||||||||
| ITB Therapy | 3 | |||||||||||
| Best Medical Treatment (BMT) | 4 | |||||||||||
| Best Medical Treatment (BMT) | 14 | |||||||||||
28 reviews available for dantrolene and Muscle Spasticity
| Article | Year |
|---|---|
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze | 2016 |
Spasticity: revisiting the role and the individual value of several pharmacological treatments.
Topics: Amines; Baclofen; Botulinum Toxins; Calcium Channel Blockers; Clonidine; Cyclohexanecarboxylic Acids | 2010 |
Pharmacologic treatment of spasticity in children.
Topics: Age Factors; Baclofen; Botulinum Toxins; Child; Clonidine; Dantrolene; Diazepam; Humans; Injections, | 2010 |
Pharmacotherapy of spasticity in children with cerebral palsy.
Topics: Baclofen; Benzodiazepines; Cerebral Palsy; Child; Clonidine; Dantrolene; Humans; Muscle Spasticity; | 2011 |
[Pharmacological treatment of spasticity in multiple sclerosis].
Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant | 2012 |
[Dantrolene. Pharmacological and therapeutic aspects].
Topics: Dantrolene; Drug Interactions; Hallucinogens; Humans; Malignant Hyperthermia; Muscle Relaxants, Cent | 2003 |
Antispasticity medications: uses and limitations of enteral therapy.
Topics: 4-Aminopyridine; Acetates; Adrenergic alpha-Agonists; Amines; Baclofen; Benzodiazepines; Cyclohexane | 2004 |
[Pharmacology and upper limb poststroke spasticity: a review. International Society of Prosthetics and Orthotics].
Topics: Arm; Baclofen; Botulinum Toxins, Type A; Clonidine; Combined Modality Therapy; Dantrolene; Ergonomic | 2004 |
Pharmacologic interventions for reducing spasticity in cerebral palsy.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Age Factors; Anti-Infective Agents, Local; Baclofen | 2005 |
[Pleural effusion associated with long-term dantrolene administration in three patients with severe motor and intellectual disabilities].
Topics: Adult; Dantrolene; Diagnosis, Differential; Disabled Persons; Eosinophilia; Female; Humans; Intellec | 2006 |
Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.
Topics: Baclofen; Clonidine; Dantrolene; Humans; Muscle Relaxants, Central; Muscle Spasticity; Randomized Co | 2006 |
The pharmacological management of spasticity.
Topics: Baclofen; Clonidine; Dantrolene; Humans; Muscle Relaxants, Central; Muscle Spasticity | 2006 |
Dantrolene.
Topics: Animals; Calcium; Dantrolene; Humans; In Vitro Techniques; Malignant Hyperthermia; Motor Neurons; Mu | 1984 |
Antispastic medication. A review.
Topics: Baclofen; Dantrolene; Diazepam; Electromyography; Humans; Muscle Spasticity | 1981 |
Spasticity: medical and surgical treatment.
Topics: Ambulatory Care; Ataxia; Baclofen; Dantrolene; Diazepam; Electric Stimulation; Electrodes; Electroen | 1980 |
Local treatment of spasticity.
Topics: Baclofen; Dantrolene; Diazepam; Humans; Muscle Spasticity; Nerve Block; Phenol; Phenols; Physical Th | 1993 |
Drugs used to treat spasticity.
Topics: Baclofen; Clonidine; Dantrolene; Diazepam; Drug Administration Schedule; Humans; Muscle Relaxants, C | 2000 |
Principles of pharmaceutical management of spastic hypertonia.
Topics: Anti-Dyskinesia Agents; Baclofen; Benzodiazepines; Botulinum Toxins; Brain Injuries; Clonidine; Dant | 2001 |
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin | 2001 |
Pharmacology of spasticity.
Topics: Baclofen; Benzodiazepines; Dantrolene; Humans; Muscle Spasticity; Neurotransmitter Agents; Phenothia | 1978 |
Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity.
Topics: Adult; Animals; Cats; Cerebral Palsy; Chemical and Drug Induced Liver Injury; Child; Clinical Trials | 1977 |
Electromyographic investigation of spasticity and muscle spasm.
Topics: Animals; Dantrolene; Drug Evaluation; Electromyography; Humans; Muscle Spasticity; Neural Conduction | 1976 |
[Spasticity: therapy of increased reflexes or movement disorder?].
Topics: Baclofen; Clonidine; Combined Modality Therapy; Dantrolene; Diazepam; Glycine; Humans; Locomotion; M | 1990 |
Antispasticity drugs: mechanisms of action.
Topics: Adrenergic alpha-Antagonists; Animals; Anticonvulsants; Baclofen; Benzodiazepines; Central Nervous S | 1985 |
Management of spasticity.
Topics: Baclofen; Dantrolene; Diazepam; Electric Stimulation Therapy; Humans; Injections, Spinal; Muscle Spa | 1988 |
Pharmacotherapy of spasticity: some theoretical and practical considerations.
Topics: Baclofen; Benzodiazepines; Clonidine; Dantrolene; Humans; Muscle Spasticity; Parasympatholytics | 1987 |
Spasticity and drug therapy.
Topics: Baclofen; Dantrolene; Humans; Muscle Spasticity | 1987 |
Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.
Topics: Animals; Calcium; Central Nervous System; Dantrolene; Endocrine Glands; Heat Exhaustion; Humans; Kin | 1986 |
17 trials available for dantrolene and Muscle Spasticity
| Article | Year |
|---|---|
Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity.
Topics: Administration, Oral; Aged; Baclofen; Benzodiazepines; Clonidine; Dantrolene; Female; Humans; Infusi | 2018 |
Long-term treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function.
Topics: Aged; Cerebrovascular Disorders; Dantrolene; Dose-Response Relationship, Drug; Double-Blind Method; | 1984 |
Dantrolene sodium suspension in treatment of spastic cerebral palsy.
Topics: Activities of Daily Living; Administration, Oral; Adolescent; Cerebral Palsy; Child; Child, Preschoo | 1980 |
[Treatment of spasticity with dantrolene sodium].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Dantrolene; Female; Humans; Male; Middle Aged; Mu | 1980 |
Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity.
Topics: Adult; Animals; Cats; Cerebral Palsy; Chemical and Drug Induced Liver Injury; Child; Clinical Trials | 1977 |
[Dantrolene in the treatment of spasticity].
Topics: Clinical Trials as Topic; Dantrolene; Double-Blind Method; Humans; Hydantoins; Muscle Spasticity | 1978 |
Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Dantrolene; Double-Blind Method; Female; Hum | 1978 |
Effect of dantrolene sodium on the incidence of seizures in children with spasticity.
Topics: Adolescent; Anticonvulsants; Cerebral Palsy; Child; Child, Preschool; Clinical Trials as Topic; Dant | 1979 |
Dantrolene sodium: long-term effects in patients with muscle spasticity.
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Dantrolene; Drug Evaluation; Female; Humans; Hyd | 1976 |
Comparison of dantrolene sodium and diazepam in the treatment of spasticity.
Topics: Clinical Trials as Topic; Dantrolene; Diazepam; Humans; Hydantoins; Multiple Sclerosis; Muscle Spast | 1976 |
Medical treatment for spasticity in children with cerebral palsy.
Topics: Cerebral Palsy; Child; Child, Preschool; Clinical Trials as Topic; Dantrolene; Diazepam; Female; Hum | 1976 |
Evaluation of a muscle relaxant: dantrolene sodium (Dantrium).
Topics: Activities of Daily Living; Administration, Oral; Adult; Age Factors; Animals; Child; Clinical Trial | 1975 |
Objective assessment of spasticity, strength, and function with early exhibition of dantrolene sodium after cerebrovascular accident: a randomized double-blind study.
Topics: Aged; Aged, 80 and over; Cerebrovascular Disorders; Dantrolene; Double-Blind Method; Female; Humans; | 1992 |
Special considerations for research with pharmacologic agents.
Topics: Animals; Dantrolene; Drug Evaluation; Humans; Muscle Spasticity; Pharmacology; Placebos; Research; R | 1991 |
[Attenuating effect of a new pharmacological agent (Dantrolene sodium) on spasticity].
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Dantrolene; Evaluation Studies as Topic; Humans; | 1973 |
A comparison of dantrolene sodium and diazepam in the treatment of spasticity.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clinical Trials as Topic; Dantrolene; Diazepam; | 1974 |
The effect of dantrolene sodium on spasticity in multiple sclerosis.
Topics: Adult; Aged; Dantrolene; Evaluation Studies as Topic; Female; Humans; Hydantoins; Male; Middle Aged; | 1973 |
52 other studies available for dantrolene and Muscle Spasticity
| Article | Year |
|---|---|
Novel Treatment Using Intravenous Dantrolene Sodium for Postoperative Exacerbated Spasticity in Multiple Sclerosis: A Case Report.
Topics: Administration, Intravenous; Dantrolene; Female; Humans; Middle Aged; Motor Neurons; Multiple Sclero | 2018 |
Adherence associated with oral medications in the treatment of spasticity.
Topics: Administration, Oral; Adult; Baclofen; Clonidine; Dantrolene; Female; Humans; Male; Medication Adher | 2013 |
[Comparative effectiveness of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity].
Topics: Aged; Baclofen; Clonidine; Comparative Effectiveness Research; Dantrolene; Female; Humans; Male; Mus | 2013 |
Pharyngeal spasticity due to dantrolene.
Topics: Baclofen; Child; Dantrolene; Deglutition Disorders; Drug Therapy, Combination; Humans; Male; Muscle | 2014 |
[Pathogenetic therapy of spasticity].
Topics: Adult; Aged; Animals; Cerebral Palsy; Child; Controlled Clinical Trials as Topic; Dantrolene; Diseas | 2008 |
Severe acneiform eruption exacerbated by dantrolene sodium.
Topics: Acneiform Eruptions; Adult; Aged; Dantrolene; Female; Humans; Middle Aged; Muscle Relaxants, Central | 2009 |
Dantrolene: new indication. Cerebral palsy in children: uncertain clinical benefit.
Topics: Cerebral Palsy; Child; Dantrolene; Drug Approval; France; Humans; Muscle Relaxants, Central; Muscle | 2008 |
Efficacy of dantrolene sodium in the treatment of spasticity.
Topics: Activities of Daily Living; Adult; Cross-Over Studies; Dantrolene; Dose-Response Relationship, Drug; | 1974 |
Management of spasticity on neurophysiological basis.
Topics: Baclofen; Chlorpromazine; Cryosurgery; Curare; Dantrolene; Diazepam; Humans; Moxisylyte; Muscle Spas | 1980 |
Drug therapy: spasticity (first of two parts).
Topics: Baclofen; Dantrolene; Diazepam; Humans; Motor Neurons; Muscle Contraction; Muscle Spasticity; Muscle | 1981 |
Acne induced by dantrolene.
Topics: Acne Vulgaris; Adult; Dantrolene; Female; Humans; Male; Middle Aged; Muscle Spasticity; Paraplegia | 1981 |
The drug treatment of spasticity.
Topics: Baclofen; Clonidine; Dantrolene; Diazepam; Humans; Muscle Spasticity; Parasympatholytics | 1983 |
Pneumonitis, pleural effusion and pericarditis following treatment with dantrolene.
Topics: Adult; Dantrolene; Female; Humans; Muscle Spasticity; Pericarditis; Pleural Effusion; Pneumonia; Rad | 1984 |
Medical treatment of spasticity.
Topics: Baclofen; Dantrolene; Diazepam; Humans; Injections, Spinal; Mephenesin; Muscle Relaxants, Central; M | 1980 |
Dantrolene and lymphocytic lymphoma.
Topics: Dantrolene; Humans; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Muscle Spasticity; Pa | 1980 |
Antispastic medication.
Topics: Baclofen; Dantrolene; Diazepam; Humans; Muscle Spasticity | 1980 |
Managing spasticity.
Topics: Adult; Baclofen; Child, Preschool; Cold Temperature; Dantrolene; Diazepam; Female; Humans; Muscle Sp | 1982 |
Management of pediatric spasticity.
Topics: Baclofen; Child; Child, Preschool; Dantrolene; Diazepam; Humans; Infant; Muscle Spasticity; Occupati | 1982 |
The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration.
Topics: Adult; Aged; Brain Concussion; Dantrolene; Dose-Response Relationship, Drug; Female; Humans; Male; M | 1981 |
Pharmacologic and surgical therapy for spasticity.
Topics: Baclofen; Dantrolene; Diazepam; Humans; Muscle Spasticity; Spinal Cord | 1981 |
Management of spasticity in spinal cord injury.
Topics: Baclofen; Benzodiazepines; Dantrolene; Humans; Muscle Spasticity; Phenothiazines; Spinal Cord Injuri | 1981 |
The action of dantrolene sodium on rat fast and slow muscle in vivo.
Topics: Animals; Dantrolene; Electric Stimulation; Female; Motor Neurons; Muscle Contraction; Muscle Spastic | 1981 |
[When and how to prescribe muscle relaxants in spasticity ?].
Topics: Baclofen; Dantrolene; Diazepam; Humans; Muscle Relaxants, Central; Muscle Spasticity | 1981 |
Treatment of spasticity.
Topics: Baclofen; Benzodiazepines; Curare; Dantrolene; Humans; Muscle Spasticity; Phenols; Propylene Glycols | 1981 |
Spasticity: current concepts of management.
Topics: Butyrates; Dantrolene; Humans; Muscle Spasticity; Physical Therapy Modalities; Sclerosing Solutions | 1980 |
[Treatment of spasticity in neurological disease by dantrolen-sodium (author's transl)].
Topics: Adolescent; Adult; Aged; Dantrolene; Female; Hemiplegia; Humans; Male; Middle Aged; Multiple Scleros | 1980 |
Dantrolene treatment for abrupt intrathecal baclofen withdrawal.
Topics: Adult; Baclofen; Dantrolene; Fever; Humans; Male; Muscle Spasticity; Spinal Cord Injuries; Substance | 1995 |
The management of cerebral palsy: subjectivity and a conundrum.
Topics: Baclofen; Botulinum Toxins; Cerebral Palsy; Dantrolene; Humans; Muscle Relaxants, Central; Muscle Sp | 1996 |
[The pharmacology of spasticity].
Topics: Baclofen; Benzodiazepines; Dantrolene; GABA Agents; Humans; Muscle Relaxants, Central; Muscle Spasti | 1980 |
Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure.
Topics: Adult; Baclofen; Catheters, Indwelling; Dantrolene; Disseminated Intravascular Coagulation; Equipmen | 1998 |
[Dantrolene-induced pleurisy: a case report].
Topics: Aged; Dantrolene; Follow-Up Studies; Humans; Male; Muscle Relaxants, Central; Muscle Spasticity; Ple | 2000 |
Eosinophilic pleural effusion due to dantrolene: resolution with steroid therapy.
Topics: Adult; Anti-Inflammatory Agents; Dantrolene; Drug Hypersensitivity; Eosinophilia; Humans; Male; Musc | 2001 |
Action of dantrolene sodium in spasticity with low dependence on fusimotor drive.
Topics: Adult; Aged; Dantrolene; Drug Evaluation; Female; Humans; Hydantoins; Male; Middle Aged; Motor Activ | 1976 |
Mode of action of dantrolene sodium in spasticity.
Topics: Dantrolene; Drug Evaluation; Electromyography; Humans; Injections, Intravenous; Motor Neurons; Multi | 1979 |
Mode of action of dantrolene sodium in spasticity.
Topics: Dantrolene; Drug Evaluation; Electromyography; Humans; Injections, Intravenous; Motor Neurons; Multi | 1979 |
Mode of action of dantrolene sodium in spasticity.
Topics: Dantrolene; Drug Evaluation; Electromyography; Humans; Injections, Intravenous; Motor Neurons; Multi | 1979 |
Mode of action of dantrolene sodium in spasticity.
Topics: Dantrolene; Drug Evaluation; Electromyography; Humans; Injections, Intravenous; Motor Neurons; Multi | 1979 |
[Muscle spasms in patients with amyotrophic lateral sclerosis (clinico-electromyographnic analysis)].
Topics: Amyotrophic Lateral Sclerosis; Carisoprodol; Dantrolene; Electromyography; Humans; Motor Neurons; Mo | 1979 |
Relationship between plasma concentration and effect of dantrolene sodium in man.
Topics: Adult; Dantrolene; Dose-Response Relationship, Drug; Female; Humans; Hydroxylation; Male; Muscle Con | 1979 |
Pleuropericardial reaction to treatment with dantrolene.
Topics: Acute Disease; Adult; Chronic Disease; Dantrolene; Female; Humans; Male; Middle Aged; Muscle Spastic | 1979 |
Effect of dantrolene sodium on the spastic external urethral sphincter recorded by sphincterometry.
Topics: Dantrolene; Female; Humans; Hydantoins; Male; Muscle Spasticity; Muscles; Paraplegia; Pressure; Uret | 1978 |
[Effect of Dantrium on spasticity in paraplegic and tetraplegic patients (author's transl)].
Topics: Adolescent; Adult; Dantrolene; Drug Evaluation; Drug Tolerance; Female; Humans; Male; Middle Aged; M | 1978 |
Dantrium--torque induced motion ("TIM"). Analysis in normal subjects.
Topics: Adult; Dantrolene; Female; Humans; Hydantoins; Male; Muscle Contraction; Muscle Spasticity | 1977 |
Clinical management of spastic states.
Topics: Baclofen; Dantrolene; Diazepam; Humans; Muscle Spasticity; Neurosurgery; Propylene Glycols; Sclerosi | 1976 |
[Sodium dantrolene (dantrium) in the treatment of neurogenic muscular spasm].
Topics: Adolescent; Adult; Aged; Cerebral Palsy; Cerebrovascular Disorders; Child; Child, Preschool; Dantrol | 1976 |
[Satoyoshi's syndrome: a syndrome of progressive muscle spasm, alopecia, and diarrhea].
Topics: Adolescent; Adult; Alopecia; Baclofen; Child; Dantrolene; Diarrhea; Humans; Male; Muscle Spasticity; | 1990 |
Long-term treatment of spasticity in children with cerebral palsy.
Topics: Cerebral Palsy; Child; Dantrolene; Gait; Humans; Long-Term Care; Muscle Spasticity | 1987 |
[Antispastic treatment of paraplegic patients].
Topics: Baclofen; Contracture; Dantrolene; Diazepam; Humans; Muscle Spasticity; Nursing Care; Paraplegia | 1988 |
The physiology of spasticity and its response to therapy.
Topics: Animals; Baclofen; Central Nervous System Diseases; Dantrolene; Diazepam; Humans; Motor Neurons; Mus | 1988 |
Muscle relaxants in multiple sclerosis.
Topics: Baclofen; Dantrolene; Humans; Multiple Sclerosis; Muscle Spasticity | 1987 |
[Antispastic agents].
Topics: Adult; Baclofen; Benzodiazepines; Child; Dantrolene; Diazepam; Drug Tolerance; Humans; Muscle Spasti | 1986 |
The effect of Dantrium on spasticity in multiple sclerosis.
Topics: Administration, Oral; Adult; Dantrolene; Depression, Chemical; Electromyography; Female; Humans; Hyd | 1974 |
Neurophysiologic mechanisms of hemiplegic and paraplegic spasticity: implications for therapy.
Topics: Ankle; Dantrolene; Diazepam; Electromyography; Hemiplegia; Humans; Knee; Motor Neurons; Muscle Relax | 1974 |
Letter: Dantrolene.
Topics: Adolescent; Constipation; Dantrolene; Female; Humans; Hydantoins; Intestinal Obstruction; Middle Age | 1974 |
Dantrolene sodium for treatment of spasticity.
Topics: Dantrolene; Humans; Hydantoins; Muscle Contraction; Muscle Relaxants, Central; Muscle Spasticity | 1974 |